Jixing Pharmaceuticals
Pharmaceuticals, 4505 Emperor BLVD, Shanghai, North Carolina, 27703, United States, 51-200 Employees
Phone Number: +12*********
Who is JIXING PHARMACEUTICALS
JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients in China with serious and life-threatening d...
Read More
-
Headquarters: 4505 Emperor BLVD, Shanghai, North Carolina, 27703, United States
-
Date Founded: 2019
-
Employees: 51-200
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from JIXING PHARMACEUTICALS
Jixing Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Jixing Pharmaceuticals
Answer: Jixing Pharmaceuticals's headquarters are located at 4505 Emperor BLVD, Shanghai, North Carolina, 27703, United States
Answer: Jixing Pharmaceuticals's phone number is +12*********
Answer: Jixing Pharmaceuticals's official website is https://jixing.com
Answer: Jixing Pharmaceuticals's revenue is $100 Million to $250 Million
Answer: Jixing Pharmaceuticals's SIC: 2834
Answer: Jixing Pharmaceuticals's NAICS: 325412
Answer: Jixing Pharmaceuticals has 51-200 employees
Answer: Jixing Pharmaceuticals is in Pharmaceuticals
Answer: Jixing Pharmaceuticals contact info: Phone number: +12********* Website: https://jixing.com
Answer: JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients in China with serious and life-threatening diseases. Backed by RTW Investments, LP, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, seasoned management team, and patient-centric focus, JIXING is dedicated to delivering a meaningful and lasting impact on patients in China. JIXINGs cardiovascular portfolio includes 3 assets in late-stage clinical development (Aficamten, Etripamil, Omecamtiv Mecarbil) and 1 in pre-clinical stage (JX09). JIXINGs ophthalmology portfolio includes 4 assets in late-stage clinical development (varenicline solution nasal spray/US brand name TYRVAYA, OC-02 nasal spray, JX06/LNZ100, JX07/LNZ101) and 1 asset in pre-clinical stage (JX08).
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month